Cyclerion Therapeutics (NASDAQ:KRSA) Stock Picked Up by Analysts at Wedbush

Analysts at Wedbush assumed coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a report released on Monday, MarketBeat reports. The brokerage set an “outperform” rating and a $44.00 price target on the stock. Wedbush’s price target indicates a potential upside of 38.50% from the company’s current price.

KRSA has been the subject of a number of other reports. Guggenheim started coverage on Cyclerion Therapeutics in a report on Monday, September 28th. They issued a “buy” rating and a $70.00 price target for the company. Stifel Nicolaus initiated coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating and a $43.00 price objective for the company. UBS Group initiated coverage on shares of Cyclerion Therapeutics in a research note on Friday, September 11th. They set a “buy” rating and a $55.00 target price for the company. Wall Street Zen raised shares of Cyclerion Therapeutics to a “sell” rating in a report on Saturday. Finally, TD Cowen assumed coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Cyclerion Therapeutics currently has an average rating of “Buy” and a consensus target price of $53.00.

Cyclerion Therapeutics Price Performance

NASDAQ:KRSA opened at $31.77 on Monday. Cyclerion Therapeutics has a one year low of $7.19 and a one year high of $59.36. The stock has a market capitalization of $21.29 million, a P/E ratio of -2.73 and a beta of 1.72.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.